28-Aug-2014 - Pfizer is rumoured to be eyeing up Actavis three months after failing to woo AstraZeneca in a $120bn megamerger, but what would such a deal bring to the Pharma Giant? In-Pharmatechnologist investigates.
22-Aug-2014 - GE Healthcare has said it plans to relocate operations in New Jersey to its new Massachusetts life sciences headquarters.
21-Aug-2014 - Ben Venue Laboratories will remain inactive says new owner Hikma as it looks to optimise its injectables manufacturing network.
20-Aug-2014 - Novartis has invested $35m (€26.3m) for a 15% stake in Israel-based Gamida Cell, which offers stem cell expansion technologies and therapeutics.
18-Aug-2014 - Access to portable and flexible technology could be one way of containing transmissible diseases says G-CON as it launches a more readily deployable version of its ‘POD’ manufacturing suite.
14-Aug-2014 - GMP failures at an aseptic plant owned by SCM Pharma are part of a wider industry trend affecting several sterile sites in the UK, according to the ex-owner of the CDMO.
13-Aug-2014 - German jobs are safe despite a programme that will cut the cost of operations by 15%, Boehringer Ingelheim says as it reacts to international price reductions.
13-Aug-2014 - Merck Millipore, the life science division of Merck KGaA, will invest €12m ($16m) at its Molsheim, France facility to expand its ready-to-use media manufacturing capabilities and capacity.
07-Aug-2014 - Codexis has felt the impact of Gilead’s Sovaldi with product revenues tumbling almost 60% due to the reduction in its hepatitis C biocatalyst and intermediate business.
05-Aug-2014 - Fresenius Kabi has recommenced production at a troubled Indian facility and expects to start shipping APIs to the US in the next few weeks.
30-Jul-2014 - Amgen is slashing 15% of its workforce and closing two US manufacturing facilities as part of a restructure the firm says will save $700m (€520m) a year.
29-Jul-2014 - Robust quality systems differentiate Biocon from other Indian manufacturers, the firm says, despite political turmoil in the Middle East and North Africa impacting first quarter 2015 sales.
29-Jul-2014 - Analytic science company Waters has acquired all of the assets of MediMass, which includes its Rapid Evaporative Ionization Mass Spectrometry (REIMS) technology, as well as patent applications, software, databases and REIMS expertise.
23-Jul-2014 - Patent expiration and a large molecule pipeline has prompted Eli Lilly to repurpose a solid oral dose plant in Indiana.
22-Jul-2014 - Botox maker Allergan announced sales and earnings per share growth above the high end of its expectations, but it will cut 1,500 jobs, or about 13% of its workforce as it continues to avoid a $54bn hostile takeover bid from Valeant Pharmaceuticals.
21-Jul-2014 - India-based Glenmark Pharmaceuticals has announced plans to set up a new oral solid dosage manufacturing facility in North Carolina.
15-Jul-2014 - Biocatalyst developer Codexis says its new platform licensing deal with GSK is a model with which it can approach other Big Pharma firms.
11-Jul-2014 - Pfizer says 100 workers at an Irish facility will now keep their jobs due to an unpredicted increase in production volumes of off-patent drugs.
10-Jul-2014 - Actavis says it is closing facilities in St. Louis, Missouri affecting 190 jobs a week after completing the $28bn (€21bn) acquisition of Forest Laboratories.
10-Jul-2014 - G-CON says a multi-million dollar investment by Pfizer could hasten the “paradigm shift” in pharma manufacturing towards flexible cleanroom technology and portable facility design.
08-Jul-2014 - Finished dosage form and API manufacturer Xellia has acquired a US plant from Fresenius Kabi in a deal it says enhances supply chain security.
08-Jul-2014 - M+W says a lack of synergies with its engineering and construction business drove the decision to sell its automation divison to ATS for €255m ($348m).
01-Jul-2014 - With its purchase of Veropharm for up to $495m, Abbott is looking to tap into one of the largest Russian manufacturers of pharmaceuticals.
30-Jun-2014 - Chinese pharma is looking for added value and “famous brands” from its processing providers, the tableting and packaging supplier Romaco has said.
25-Jun-2014 - The United States Food and Drug Administration (FDA) has announced it will consider products outside the nanoscale, up to 1,000 nanometres (nm), to involve nanotechnology and so be potentially liable for “particular examination.”
GMP failures at an aseptic plant owned by SCM Pharma are part of a wider industry trend...
German jobs are safe despite a programme that will cut the cost of operations by 15%, Boehringer...
Efficacy and safety data from use of unapproved Ebola virus treatments should be shared according to an...
A previously unknown signaling platform may be responsible for the success of the main psychoactive ingredient in...
In order to ensure uniformity on the state and federal levels, India’s CDSCO (Central Drugs Standard Control...
Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its...